ABILITY Neurotech wins approval for the first long-term trial of its wireless brain-computer interface in ALS patients.
Brain-computer interfaces (BCI) have spent years occupying a strange space between breakthrough science and science fiction. Most people have heard the promise by now: devices that can translate brain activity into commands, allowing people with paralysis or severe neurological conditions to communicate again. However, outside carefully controlled demonstrations, very few systems have made the leap into everyday life.
That is what makes the latest milestone from ABILITY Neurotech significant. The Switzerland-based neurotechnology company has received Investigational Medical Device Dossier (IMDD) approval in the Netherlands to begin the first chronic implantation study of its fully implantable optical-link brain-computer interface (BCI) in patients with amyotrophic lateral sclerosis (ALS) [1]. The trial will take place at University Medical Center Utrecht, one of Europe’s leading BCI research centers.
Unlike short-term surgical tests that last hours or days, chronic implantation means the device will remain implanted long-term, allowing researchers to see whether it can genuinely support communication in daily life – at home, outside the hospital and beyond the tightly managed conditions of a lab.
For years, much of the BCI sector has focused on proving that neural interfaces can work. ABILITY’s approval signals that the industry is increasingly being pushed to show whether these systems can become practical technologies that people can actually live with.
“Receiving approval for our first chronic implantation study is a defining moment for both ABILITY and for the broader BCI field,” said Dr Rotem Kopel, CEO of ABILITY Neurotech. “The industry has long focused on proving neural interfaces can work in controlled environments. This study moves the field significantly in the direction of delivering a practical and scalable system patients can use independently in everyday life.”
ABILITY’s device is designed for people with severe motor impairment, including ALS patients who may gradually lose the ability to speak or move while remaining cognitively aware. The company says the implant could eventually allow users to generate text, interact with assistive technologies and communicate through thought-driven commands. Importantly, the system is intended for home use, not only clinical supervision.
One reason BCIs have struggled to scale is that many systems are cumbersome. Some rely on external hardware, frequent charging or bulky components that make long-term use difficult.
ABILITY is attempting to sidestep some of those limitations with a minimally invasive, battery-free implant that sits beneath the scalp and transmits neural signals through an infrared optical link.
In simpler terms, instead of relying on conventional wireless systems that can limit data transmission, the implant uses light-based communication to transmit detailed brain signals. The company says this allows it to capture richer neural information while keeping the device fully implanted and wire-free.
“For patients with severe motor impairment, the loss of communication is devastating,” said Dr Mariska Vansteensel, clinical lead at UMC Utrecht for the INTRECOM consortium overseeing the study. “Implantable BCI’s represent an important step towards restoring a reliable means of interaction and independence for people who are otherwise locked inside their own bodies.”
Moreover, the BCI market has become increasingly crowded over the last few years, fueled by advances in AI, neural engineering and investor enthusiasm surrounding next-generation human-machine interfaces. However, the field is also entering a more mature phase, where durability, safety, usability and regulatory progress may matter more than headline-grabbing demos.
ABILITY’s approval reflects that transition. Rather than framing the technology as a futuristic augmentation, the company is positioning its platform around long-term clinical utility: restoring communication, autonomy and quality of life for people living with debilitating neurological conditions.
Longevity.Technology: That also connects directly to a larger conversation happening across longevity and healthspan science. As populations age, preserving independence is becoming just as important as extending lifespan itself. Technologies that help people maintain agency, communication and cognitive participation could become central to how societies define healthy aging in the decades ahead.
ALS remains one of the most devastating neurodegenerative diseases precisely because it progressively strips away physical function while often leaving mental awareness intact. Tools that restore even part of that lost interaction carry implications far beyond convenience – they touch identity, dignity and social connection.
The trial at UMC Utrecht, alongside a planned follow-up study in Graz, Austria, will now test whether ABILITY’s platform can deliver on those ambitions outside controlled demonstrations.
For the BCI sector, it is another step toward legitimacy. For longevity science, it is a reminder that the future of healthy aging may depend on preserving the ability to remain connected to the world around us, not only on adding years to life.
